Please login to the form below

Not currently logged in
Email:
Password:

Abilify Maintena

This page shows the latest Abilify Maintena news and features for those working in and with pharma, biotech and healthcare.

Abilify Maintena launches in Europe

Abilify Maintena launches in Europe

Abilify Maintena launches in Europe. Schizophrenia treatment is a key product to help Lundbeck replace lost Cipralex sales. ... Lundbeck said today that Abilify Maintena will be on the market in 10 countries by the end of year.

Latest news

  • Otsuka/Lundbeck say brexpiprazole works in phase III trial Otsuka/Lundbeck say brexpiprazole works in phase III trial

    Approval would reinforce Lundbeck and Otsuka's central nervous system franchise, which was also boosted last year by the approval of a once-monthly formulation of aripiprazole - Abilify Maintena - which is ... Lundbeck and Otsuka renewed their CNS

  • Ipragliflozin beats diabetes rivals to Japanese approval Ipragliflozin beats diabetes rivals to Japanese approval

    2010. - Otsuka Pharmaceutical has filed for approval of its once-monthly intramuscular formulation of antipsychotic Abilify (aripiprazole) as a maintenance treatment for schizophrenia. ... The product was launched in the US last year under the Abilify

  • Profits down at Lundbeck as revenues slip Profits down at Lundbeck as revenues slip

    and depot antipsychotic Abilify Maintena (aripiprazole). ... Lundbeck said uptake of Abilify Maintena is "encouraging", although it did not break out sales figure for the drug, which reached the US market in March 2013 and has been recommended

  • EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

    Otsuka also received good news, winning CHMP backing for schizophrenia treatment Abilify Maintena (aripiprazole). ... The medicine is an extended release injectable version of Abilify, which is marketed by Otsuka as part of a collaboration with Lundbeck.

  • Lundbeck losses deepen on EU fine Lundbeck losses deepen on EU fine

    Other recent launches, such as alcoholism therapy Selincro (nalmefene) and depot antipsychotic Abilify Maintena (aripiprazole), are also off to a good start, said the company, although it did not reveal early ... Lundbeck also has two projects in phase

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    At the end of February, the FDA approved Abilify Maintena (aripiprazole), an intramuscular extended-release depot formulation for the treatment of schizophrenia and the first commercialised product to evolve from this ... injectable in 14 European

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics